← Evidence map

ArticleWellcome open research2025

Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda.

Peter Olupot-Olupot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda. | OpenQuestion